Levodopa infusion solution

An aqueous pharmaceutical solution, comprising

• at least 5 mg/ml dissolved levodopa and having a pH in the range of 3.0 to 8.5, wherein said solution is formed by combining and continually mixing:
• a) an aqueous stock solution comprising levodopa and having a pH of less than 2.8 at 25° C., and
• b) an aqueous buffering solution for increasing the pH of said stock solution, comprising at least one buffer component, said buffering solution having a pH of at least 4.0 at 25° C.,
• wherein the mixture is free of precipitated levodopa and/or wherein less than 15 wt % of levodopa has degraded over a period of 2 hours after the stock solution and the buffering solution are combined.

A kit for providing an aqueous pharmaceutical solution, comprising at least 5 mg/ml dissolved levodopa and having a pH in the range of 3.0 to 8.5, said kit comprising:

• a) an aqueous stock solution comprising levodopa and having a pH of less than 2.8 at 25° C.,
• b) an aqueous buffering solution for increasing the pH of said aqueous stock solution, comprising a buffer and having a pH of at least 4.0 at 25° C.;
• c) mixing means for mixing said solutions a) and b);
• and
• d) an output means for delivering a mixed solution from the mixing means of step c).

A kit for providing an aqueous pharmaceutical solution, comprising:

• I) an aqueous stock solution having of pH of less than 2.8 at 25° C. and comprising;
• a) aqua sterile,
• b) levodopa,
• c) at least one enzyme inhibitor,
• d) at least one physiologically acceptable acid, and
• e) at least one a stabilizer, and
• II) an aqueous buffering solution having a pH of at least 4.0 at 25° C. and comprising;
• f) aqua sterile,
• g) at least one buffer component, and
• h) at least one stabilizer and/or solubilizer.